Determination of Biomarkers of the Effectiveness of Deep Brain Stimulation by Direct Electrophysiological Recordings of Brain Activity in a Cognitive Context - LFP-DBS 2024

Launched by CENTRE HOSPITALIER ST ANNE · Feb 3, 2025

Keywords

ClinConnect Summary

This clinical trial, called LFP-DBS 2024, is looking at how to make deep brain stimulation (DBS) more effective for patients with certain neurological and psychiatric conditions, like Parkinson's disease, essential tremors, and depression. DBS involves implanting electrodes in the brain to deliver electrical stimulation, which can help manage symptoms when other treatments are not working. The researchers want to identify specific markers or signs that can predict how well this treatment will work for each individual. By collecting detailed information during the procedure, they hope to better tailor the stimulation to each patient's needs.

To participate in this trial, you must be an adult experiencing a condition that requires DBS. You should be able to understand the study details and complete questionnaires in French, and you will need to give your consent to take part. However, if you have certain medical risks, like issues with anesthesia or surgery, or if you cannot perform specific tests, you may not be eligible. If you join the study, you can expect to undergo assessments that may help improve future DBS treatments for yourself and others.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient
• • Patient suffering from a pathology requiring treatment with deep brain stimulation: neurological disease (e.g.: Parkinson Disease, Essential Tremors, dystonia, epilepsy, etc.) or psychiatric disease (e.g.: Obsessive Compulsive Disorder, depression, eating disorders, etc.).
• • Patient capable of understanding the study procedures and completing the self-questionnaires in French
• • Patient informed and having signed the informed consent form
• Exclusion Criteria:
• • Contraindications to DBS, neurosurgery or anesthesia
• • Patients with significant hemorrhagic or infectious risks
• • Patient unable to perform the neurocognitive or sensorimotor tests
• • Patient who is not a beneficiary of a social security system.